Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
108.23
(
0.70%
)
Bitcoin
77,047.01
(
-0.47%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 193725

Friday, 07/31/2015 9:17:14 PM

Friday, July 31, 2015 9:17:14 PM

Post# of 257580
Re: AMGN’s threat from FoBs

http://www.wsj.com/articles/amgen-to-undergo-experimental-treatment-1438363128

At about 18 times forward earnings, Amgen stock isn’t especially pricey for a large biotech. But…for Amgen to maintain or grow its valuation, biosimilars need to arrive with a whimper, not a roar.

In 2Q15, 36% of AMGN’s product sales came from Epogen, Neupogen, and Neulasta, which are off-patent in the US and several other major countries.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today